-
公开(公告)号：US20090036364A1
公开(公告)日：2009-02-05
申请号：US11816095
申请日：2006-02-10
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
CPC分类号： C07K14/575 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20080312157A1
公开(公告)日：2008-12-18
申请号：US11840921
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20150064223A1
公开(公告)日：2015-03-05
申请号：US14370449
申请日：2012-07-11
IPC分类号： A61K31/155 , A61K31/55 , A61K9/20 , A61K31/357 , A61K31/485 , A61K45/06 , A61K31/137
CPC分类号： A61K31/155 , A61K9/2018 , A61K9/2054 , A61K9/209 , A61K9/2846 , A61K31/137 , A61K31/357 , A61K31/485 , A61K31/55 , A61K31/7048 , A61K45/06 , A61K2300/00
摘要： Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
摘要翻译： 本文提供了通过施用包含双胍或相关杂环化合物（例如二甲双胍）的组合来治疗某些病症（包括糖尿病，肥胖症和其它代谢疾病，病症或病症）的方法。 本文还提供双胍类或相关杂环化合物组合物及其制备用于本发明方法的方法。 本文还提供包含二甲双胍及其盐及其使用方法的组合物。
-
公开(公告)号：US20130303466A1
公开(公告)日：2013-11-14
申请号：US13880718
申请日：2011-10-18
IPC分类号： A61K38/06 , A61K31/4402 , A61K31/44 , A61K31/341 , A61K31/357 , A61K31/365 , A61K31/704 , A61K31/661 , A61K31/121 , A61K31/4015 , A61K31/198 , A61K31/23
CPC分类号： A61K38/06 , A61K31/121 , A61K31/198 , A61K31/23 , A61K31/231 , A61K31/341 , A61K31/357 , A61K31/365 , A61K31/401 , A61K31/4015 , A61K31/44 , A61K31/4402 , A61K31/661 , A61K31/683 , A61K31/704 , A61K45/06 , C07K5/0215 , C07K5/0808 , C07K5/0815 , C07K5/0819
摘要： Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
-
公开(公告)号：US20130281387A1
公开(公告)日：2013-10-24
申请号：US13880719
申请日：2011-10-18
IPC分类号： A61K31/706 , A61K45/06 , A61K31/194 , A61K31/165 , A61K31/255 , A61K31/661 , A61K31/662 , A61K31/44 , A61K31/5377 , A61K31/4439 , A61K31/4545 , A61K31/426 , A61K31/42 , A61K31/341 , A61K31/704 , A61K31/20 , A61K31/7008
CPC分类号： A61K31/706 , A61K31/164 , A61K31/165 , A61K31/185 , A61K31/194 , A61K31/195 , A61K31/198 , A61K31/20 , A61K31/23 , A61K31/231 , A61K31/255 , A61K31/275 , A61K31/341 , A61K31/415 , A61K31/42 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K31/661 , A61K31/662 , A61K31/7008 , A61K31/7034 , A61K31/704 , A61K45/06
摘要： Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
-
公开(公告)号：US08394765B2
公开(公告)日：2013-03-12
申请号：US11940317
申请日：2007-11-14
CPC分类号： A61K38/22 , A61K31/135 , A61K31/454 , A61K31/7048 , A61K38/2264 , A61K38/2278 , A61K2300/00
摘要： Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
摘要翻译： 公开了治疗肥胖或肥胖相关疾病的方法。 这些方法包括使用针对前脑的抗肥胖剂与针对后脑的抗肥胖剂的组合。
-
公开(公告)号：US08389473B2
公开(公告)日：2013-03-05
申请号：US12750575
申请日：2010-03-30
申请人： David R. Hathaway , Alain D. Baron
发明人： David R. Hathaway , Alain D. Baron
CPC分类号： A61K38/26 , A61K31/7004 , A61K33/00 , A61K38/2278
摘要： Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
摘要翻译： 本发明的组合物，包括与胰高血糖素样肽-1的受体结合的化合物，肠降血糖素，胰高血糖素样肽-1（GLP-1），毒蜥外泌肽或激动剂，类似物（优选激动剂 类似物），任何前述化合物的衍生物或变体，用于预防和治疗与心脏缺血，心脏缺血灌注和/或充血性心力衰竭相关的心律失常。 本发明涉及这种治疗的方法和组合物。
-
公开(公告)号：US20130338095A1
公开(公告)日：2013-12-19
申请号：US13880717
申请日：2011-10-18
IPC分类号： C07H19/20 , C07D213/56 , C07D285/16 , C07F7/08 , C07D241/24 , C07D495/04 , C07D317/68 , C07D493/04
CPC分类号： C07H19/20 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/216 , A61K31/277 , A61K31/34 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/4184 , A61K31/4192 , A61K31/42 , A61K31/423 , A61K31/44 , A61K31/4402 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/444 , A61K31/4965 , A61K31/497 , A61K31/505 , A61K31/517 , A61K31/519 , A61K31/549 , A61K31/7068 , A61K31/7076 , A61K45/06 , C07C233/11 , C07C233/51 , C07C233/65 , C07C235/34 , C07C235/46 , C07C235/48 , C07C235/78 , C07C255/57 , C07C275/30 , C07C275/34 , C07C323/62 , C07C2601/14 , C07C2602/10 , C07D213/40 , C07D213/56 , C07D241/24 , C07D285/16 , C07D317/68 , C07D333/24 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D493/04 , C07D495/04 , C07F7/0812 , C07F9/65586 , C07H7/02
摘要： Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
-
公开(公告)号：US08263545B2
公开(公告)日：2012-09-11
申请号：US11840921
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20120177730A1
公开(公告)日：2012-07-12
申请号：US13345135
申请日：2012-01-06
申请人： Alain D. BARON , Martin R. BROWN , Christopher R.G. JONES , Nigel R.A. BEELEY , Mark S. FINEMAN
发明人： Alain D. BARON , Martin R. BROWN , Christopher R.G. JONES , Nigel R.A. BEELEY , Mark S. FINEMAN
CPC分类号： A61K31/155 , A61K9/0053 , A61K9/2054 , A61K9/209 , A61K9/2846 , A61K9/4808 , A61K31/19 , A61K31/198 , A61K31/7016 , A61K31/704 , A61K45/06
摘要： Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
摘要翻译： 本文提供了通过施用包含化学感应受体配体如苦味受体配体的组合物来治疗与化学感觉受体相关的病症（包括糖尿病，肥胖症和其它代谢疾病，病症或病症）的方法。 本文还提供了化学感应受体配体组合物，包括苦味受体配体组合物及其制备用于本发明方法的方法。 本文还提供包含二甲双胍及其盐及其使用方法的组合物。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.049 秒)
